| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
RIG-1 modulator 1 targets the RIG-I pathway as a direct agonist. By activating RIG-I, it induces IFN-β expression through activation of the innate immune response. The compound facilitates enhanced antiviral signaling and has potential combinatorial effects when combined with polymerase inhibitors or immunomodulators.
|
|---|---|
| ln Vitro |
In vitro, RIG-1 modulator 1 is a potent RIG-I agonist. It activates the innate immune response and induces IFN-β expression. The compound exhibits antiviral activity against influenza virus, HBV, HCV, and HIV in cell-based assays. It is used in research on antiviral infections and tumor immunotherapy.
|
| ln Vivo |
In vivo activity of RIG-1 modulator 1 has not been extensively characterized in animal models. The compound is an antiviral research compound from a patent application. Specific in vivo efficacy studies have not been detailed in the available literature. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for RIG-1 modulator 1 typically involve studying its binding to RIG-I or its effects on RIG-I signaling. The compound is incubated with purified RIG-I protein or cell lysates, and binding is assessed using surface plasmon resonance or other biophysical methods. RIG-I activation is measured by assessing downstream signaling events.
|
| Cell Assay |
In vitro cell-based assays for RIG-1 modulator 1 typically employ cells expressing RIG-I, such as macrophages, dendritic cells, or epithelial cells. Cells are treated with various concentrations of the compound. RIG-I pathway activation is assessed by measuring IFN-β production via ELISA or qPCR, IRF3 phosphorylation by Western blot, and NF-κB activation by reporter gene assays. Antiviral activity is assessed in virus-infected cell cultures.
|
| Animal Protocol |
In vivo animal studies with RIG-1 modulator 1 have not been extensively reported. The compound is an antiviral research compound from a patent application. Future studies may involve administration of the compound in animal models of viral infection to evaluate its antiviral efficacy. Currently, no specific in vivo data are available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of RIG-1 modulator 1 have not been characterized. As a small molecule with a molecular weight of 335.45, the compound may have reasonable oral bioavailability and cell permeability. However, specific PK parameters have not been determined. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
The toxicity profile of RIG-1 modulator 1 has not been characterized. The compound is intended for research use only and is not approved for human therapeutic applications. No specific toxicology data are available. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
RIG-1 modulator 1 is a research-grade RIG-I agonist used in antiviral and tumor immunotherapy research. It is not an approved therapeutic drug and has no clinical trial history. The compound is supplied with purity ≥99%. Synonyms include 1-(2-(dimethylamino)ethyl)-3-(7-methylbenzo[1,2-d:3,4-d']bis(thiazole)-2-yl)urea.
|
| Molecular Formula |
C14H17N5OS2
|
|---|---|
| Molecular Weight |
335.447679281235
|
| Exact Mass |
335.087
|
| CAS # |
1428729-63-8
|
| PubChem CID |
71549283
|
| Appearance |
White to light yellow solid powder
|
| LogP |
2.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
411
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C(NC(NCCN(C)C)=O)=NC2=CC=C3C(=C12)N=C(C)S3
|
| InChi Key |
HORUPPJGOWQYBQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H17N5OS2/c1-8-16-11-10(21-8)5-4-9-12(11)22-14(17-9)18-13(20)15-6-7-19(2)3/h4-5H,6-7H2,1-3H3,(H2,15,17,18,20)
|
| Chemical Name |
1-[2-(dimethylamino)ethyl]-3-(7-methyl-[1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 35 mg/mL (~104.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9811 mL | 14.9054 mL | 29.8107 mL | |
| 5 mM | 0.5962 mL | 2.9811 mL | 5.9621 mL | |
| 10 mM | 0.2981 mL | 1.4905 mL | 2.9811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
